Fatima Valdes Mora

Team Leader-Cancer Epigenetic Biology and Therapeutics. CCI
Conjoint Senior Lecturer

I am a mid-early career researcher arising as an authority in cancer epigenetics, single-cell transcriptomics, and epigenomics. During my career, I have made seminal discoveries in the field of histone variants and cancer epigenetics (Genome Research 2012, Nature Comms 2017, and iScience 2019) where I demonstrated an oncogenic role for acetylation of the histone variant H2A.Z. In the last 5 years, I have also focused on cutting-edge technology implementation, single-cell RNAseq, for the understanding of tumour biology transcriptionally (Cell Reports 2021) and more recently epigenetically, single-cell ATAC-seq. One of the current main foci of my group is the understanding of the epigenetic causes of childhood cancer. https://www.ccia.org.au/about-the-institute/our-research/personalised-medicine/cancer-epigenetic-biology-and-therapeutics

I obtained my PhD in Molecular Biology, Biochemistry, and Biomedicine from CSIC (Autonoma University of Madrid, Spain) in December 2008. I completed my postdoctoral research at Prof Susan Clark’s lab (Garvan Institute, Sydney Australia) in 2013 and obtained a Group Leader appointment at Garvan in 2014 to lead the Histone Variant Group. I have recently joined the Children’s Cancer Institute as Team Leader of the “Cancer Epigenetic Biology and Therapeutics” lab. From 2014, I hold a conjoint Senior Lecturer position at UNSW Sydney that have allowed me to supervise multiple Masters, Honours, and PhD students

I have published 26 peer-reviewed papers since 2004 (15 as corresponding/first author), from which 15 have been published in the last 5 years. During my postdoctoral stage, I have attracted > €2.7 M of competitive funding (as fellowships and research grants) from both public and private Australian funding bodies, including, the highly competitive NHMRC project grants (current success rate is <10%), Cancer Institute NSW, Prostate Cancer Foundation of Australia (PCFA), National Breast Cancer Foundation (NBCF) and Cure Cancer. I currently hold a CINSW Career Development Fellowship which is allowing her to establish my own research niche in epigenomics and cancer.

I have a passion for the development and implementation of novel technology that has allowed her to develop a multidisciplinary profile. I have a strong profile in molecular biology, epigenetics, single-cell transcriptomics, next-generation sequencing and bioinformatics interpretation of genome-wide data. I perform extremely well as a hinge joint between bioinformatics and biology, interpreting and integrating sequencing data into meaningful biological outputs.

Preprints
add
Colino-Sanguino Y; Fuente LRDL; Gloss B; Law AMK; Handler K; Pajic M; Salomon R; Gallego-Ortega D; Valdes-Mora F, 2023, Systematic comparison of high throughput Single-Cell RNA-Seq platforms in complex tissues, , http://dx.doi.org/10.1101/2023.04.04.535585
2023
Araujo A; Abaurrea A; Azcoaga P; López-Velazco J; Rezola R; Osorio-Querejeta I; Valdés-Mora F; Flores J; Jenkins L; Fernández-Nogueira P; Ferrari N; Martín-Martín N; Tzankov A; Eppenberger-Castori S; Alvarez-Lopez I; Urruticoechea A; Bragado P; Coleman N; Carracedo A; Gallego-Ortega D; Calvo F; Isacke C; Caffarel M; Lawrie C, 2020, Stromal Oncostatin M axis promotes breast cancer progression, , http://dx.doi.org/10.1101/2020.10.30.356774
2020
Valdes-Mora F; Salomon R; Gloss B; Law AMK; Castillo L; Murphy K; Venhuizen J; Magenau A; Papanicolau M; Rodriguez de la Fuente L; Roden DL; Colino-Sanguino Y; Kikhtyak Z; Farbehi N; Conway JRW; Oakes SR; Sikta N; O'Donoghue SI; Cox TR; Timpson P; Ormandy CJ; Gallego Ortega D, Single Cell Transcriptomics Reveals Involution Mimicry During the Specification of the Basal Breast Cancer Subtype, , http://dx.doi.org/10.2139/ssrn.3634808
Journal articles
add
Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D’Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA, 2023, 'Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes', Scientific Reports, 13, pp. 3775, http://dx.doi.org/10.1038/s41598-023-30395-4
2023
Ganguly D; Schmidt MO; Coleman M; Ngo T-VC; Sorrelle N; Dominguez ATA; Murimwa GZ; Toombs JE; Lewis C; Fang YV; Valdes-Mora F; Gallego-Ortega D; Wellstein A; Brekken RA, 2023, 'Pleiotrophin drives a prometastatic immune niche in breast cancer.', J Exp Med, 220, http://dx.doi.org/10.1084/jem.20220610
2023
Araujo AM; Abaurrea A; Azcoaga P; López-Velazco JI; Manzano S; Rodriguez J; Rezola R; Egia-Mendikute L; Valdés-Mora F; Flores JM; Jenkins L; Pulido L; Osorio-Querejeta I; Fernández-Nogueira P; Ferrari N; Viera C; Martín-Martín N; Tzankov A; Eppenberger-Castori S; Alvarez-Lopez I; Urruticoechea A; Bragado P; Coleman N; Palazón A; Carracedo A; Gallego-Ortega D; Calvo F; Isacke CM; Caffarel MM; Lawrie CH, 2022, 'Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment', Journal of Clinical Investigation, 132, http://dx.doi.org/10.1172/JCI148667
2022
Law AMK; Chen J; Colino-Sanguino Y; Fuente LRDL; Fang G; Grimes SM; Lu H; Huang RJ; Boyle ST; Venhuizen J; Castillo L; Tavakoli J; Skhinas JN; Millar EKA; Beretov J; Rossello FJ; Tipper JL; Ormandy CJ; Samuel MS; Cox TR; Martelotto L; Jin D; Valdes-Mora F; Ji HP; Gallego-Ortega D, 2022, 'ALTEN: A High-Fidelity Primary Tissue-Engineering Platform to Assess Cellular Responses Ex Vivo', Advanced Science, 9, http://dx.doi.org/10.1002/advs.202103332
2022
Papanicolaou M; Parker AL; Yam M; Filipe EC; Wu SZ; Chitty JL; Wyllie K; Tran E; Mok E; Nadalini A; Skhinas JN; Lucas MC; Herrmann D; Nobis M; Pereira BA; Law AMK; Castillo L; Murphy KJ; Zaratzian A; Hastings JF; Croucher DR; Lim E; Oliver BG; Mora FV; Parker BL; Gallego-Ortega D; Swarbrick A; O’Toole S; Timpson P; Cox TR, 2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13, pp. 4587, http://dx.doi.org/10.1038/s41467-022-32255-7
2022
Zandavi SM; Koch FC; Vijayan A; Zanini F; Mora FV; Ortega DG; Vafaee F, 2022, 'Disentangling single-cell omics representation with a power spectral density-based feature extraction', Nucleic Acids Research, 50, pp. 5482 - 5492, http://dx.doi.org/10.1093/nar/gkac436
2022
Araujo AM; Abaurrea A; Azcoaga P; López-Velazco JI; Manzano S; Rodriguez J; Rezola R; Egia-Mendikute L; Valdés-Mora F; Flores JM; Jenkins L; Pulido L; Osorio-Querejeta I; Fernández-Nogueira P; Ferrari N; Viera C; Martín-Martín N; Tzankov A; Eppenberger-Castori S; Alvarez-Lopez I; Urruticoechea A; Bragado P; Coleman N; Palazón A; Carracedo A; Gallego-Ortega D; Calvo F; Isacke CM; Caffarel MM; Lawrie CH, 2022, 'Erratum: Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment (Journal Clinical Investigation (2022) 132:7 (e148667) 10.1172/JCI148667)', Journal of Clinical Investigation, 132, pp. e165107, http://dx.doi.org/10.1172/JCI165107
2022
Colino-Sanguino Y; Clark SJ; Valdes-Mora F, 2022, 'Erratum: The H2A.Z-nucleosome code in mammals: emerging functions (Trends in Genetics (2022) 38(3) (273–289), (S0168952521002870), (10.1016/j.tig.2021.10.003)): (Trends in Genetics, 38:3 p:273–289, 2022)', Trends in Genetics, 38, pp. 516, http://dx.doi.org/10.1016/j.tig.2022.02.004
2022
Persson M; Jackson E; Duchatel R; Bramberger L; McEwen H; Kearney P; Findlay I; Douglas A; Kobbe B; Wagener R; Larsen M; Faridi P; Holst J; Mayall J; Gedye C; Hondermarck H; Horvat J; Nixon B; Cartaxo R; Koschmann C; Valdes-Mora F; Ortega DG; Nazarian J; Alonso MM; Hulleman E; Van der Lugt J; Vitanza N; Mueller S; Dun M, 2022, 'TMIC-06. ANTAGONISM OF DRD2 USING ONC201 INCREASED EXPRESSION OF ANTIGEN PRESENTATION PATHWAY PROTEINS IN DIFFUSE MIDLINE GLIOMA, RECRUITING TUMOR INFILTRATING LYMPHOCYTES IN VIVO', Neuro-Oncology, 24, pp. vii272 - vii272, http://dx.doi.org/10.1093/neuonc/noac209.1050
2022
Dun MD; Jackson ER; Duchatel RJ; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara S; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Staudt D; Germon ZP; Skerrett-Byrne DA; Nixon B; Smith ND; Hulleman E; Day B; McCowage GB; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; Vitanza NA; Nazarian J; Koschmann C; Cain J; Mueller S, 2022, 'DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992)', Neuro-Oncology, 24, pp. i18 - i19, http://dx.doi.org/10.1093/neuonc/noac079.064
2022
Colino-Sanguino Y; Clark SJ; Valdes-Mora F, 2022, 'The H2A.Z-nuclesome code in mammals: emerging functions', Trends in Genetics, 38, pp. 273 - 289, http://dx.doi.org/10.1016/j.tig.2021.10.003
2022
Jackson E; Duchatel R; Persson M; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara S; Le Grand M; Kearney P; Douglas A; Findlay I; Staudt D; Germon Z; Skerrett-Byrne D; Nixon B; Smith N; Hulleman E; Day B; McCowage G; Alvaro F; Waszak S; Larsen M; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; Vitanza N; Nazarian J; Koschmann C; Cain J; Mueller S; Dun M, 2022, 'EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA', Neuro-Oncology, 24, pp. vii211 - vii211, http://dx.doi.org/10.1093/neuonc/noac209.811
2022
Rodriguez de la Fuente L; Law AMK; Gallego-Ortega D; Valdes-Mora F, 2021, 'Tumor dissociation of highly viable cell suspensions for single-cell omic analyses in mouse models of breast cancer', STAR Protocols, 2, pp. 100841, http://dx.doi.org/10.1016/j.xpro.2021.100841
2021
Valdés-Mora F; Salomon R; Gloss BS; Law AMK; Venhuizen J; Castillo L; Murphy KJ; Magenau A; Papanicolaou M; Rodriguez de la Fuente L; Roden DL; Colino-Sanguino Y; Kikhtyak Z; Farbehi N; Conway JRW; Sikta N; Oakes SR; Cox TR; O'Donoghue SI; Timpson P; Ormandy CJ; Gallego-Ortega D, 2021, 'Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype', Cell Reports, 35, http://dx.doi.org/10.1016/j.celrep.2021.108945
2021
Law AMK; Rodriguez de la Fuente L; Grundy TJ; Fang G; Valdes-Mora F; Gallego-Ortega D, 2021, 'Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies', Frontiers in Oncology, 11, pp. 782766, http://dx.doi.org/10.3389/fonc.2021.782766
2021
Salomon R; Martelotto L; Valdes-Mora F; Gallego-Ortega D, 2020, 'Genomic Cytometry and New Modalities for Deep Single-Cell Interrogation', Cytometry Part A, 97, pp. 1007 - 1016, http://dx.doi.org/10.1002/cyto.a.24209
2020
Law AMK; Valdes-Mora F; Gallego-Ortega D, 2020, 'Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer', Cells, 9, http://dx.doi.org/10.3390/cells9030561
2020
Salazar-Roa M; Trakala M; Álvarez-Fernández M; Valdés-Mora F; Zhong C; Muñoz J; Yu Y; Peters TJ; Graña-Castro O; Serrano R; Zapatero-Solana E; Abad M; Bueno MJ; de Cedrón MG; Fernández-Piqueras J; Serrano M; Blasco MA; Wang DZ; Clark SJ; Izpisua-Belmonte JC; Ortega S; Malumbres M, 2020, 'Transient exposure to miR-203 enhances the differentiation capacity of established pluripotent stem cells', EMBO Journal, 39, http://dx.doi.org/10.15252/embj.2019104324
2020
Khoury A; Achinger-Kawecka J; Bert SA; Smith GC; French HJ; Luu PL; Peters TJ; Du Q; Parry AJ; Valdes-Mora F; Taberlay PC; Stirzaker C; Statham AL; Clark SJ, 2020, 'Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-019-13753-7
2020
Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ, 2020, 'Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-019-14098-x
2020
Salazar-Roa M; Trakala M; Álvarez-Fernández M; Valdés-Mora F; Zhong C; Muñoz J; Yu Y; Peters T; Graña O; Serrano R; Zapatero-Solana E; Abad M; Bueno MJ; de Cedrón MG; Fernández-Piqueras J; Serrano M; Blasco M; Wang D-Z; Clark S; Izpisua-Belmonte JC; Ortega S; Malumbres M, 2019, 'A novel microRNA-based strategy to expand the differentiation potency of stem cells', , http://dx.doi.org/10.1101/826446
2019
Colino-Sanguino Y; Cornett EM; Moulder D; Smith GC; Hrit J; Cordeiro-Spinetti E; Vaughan RM; Krajewski K; Rothbart SB; Clark SJ; Valdés-Mora F, 2019, 'A Read/Write Mechanism Connects p300 Bromodomain Function to H2A.Z Acetylation', iScience, 21, pp. 773 - 788, http://dx.doi.org/10.1016/j.isci.2019.10.053
2019
Valdes-Mora F; Salomon R; Gloss B; Law AMK; Castillo L; Murphy K; Venhuizen J; Magenau A; Papanicolau M; de la Fuente LR; Roden D; Colino-Sanguino Y; Kikhtyak Z; Farbehi N; Conway JRW; Oakes S; Sikta N; O’Donoghue S; Cox T; Timpson P; Ormandy C; Gallego-Ortega D, 2019, 'Single cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype', , http://dx.doi.org/10.1101/624890
2019
Valdes-Mora F; Salomon R; Gloss B; Law AMK; Murphy K; Roden DL; Castillo L; Colino-Sanguino Y; Farbehi N; Conway J; Timpson P; Ormandy CJ; Gallego-Ortega D, 2019, 'Characterisation of developmental pathways that drive metastatic progression of breast cancer at single cell resolution', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p022
2019
Salomon R; Kaczorowski D; Valdes-Mora F; Nordon RE; Neild A; Farbehi N; Bartonicek N; Gallego-Ortega D, 2019, 'Droplet-based single cell RNAseq tools: A practical guide', Lab on a Chip, 19, pp. 1706 - 1727, http://dx.doi.org/10.1039/c8lc01239c
2019
Valdes-Mora F; Handler K; Law AMK; Salomon R; Oakes SR; Ormandy CJ; Gallego-Ortega D, 2018, 'Single-cell transcriptomics in cancer immunobiology: The future of precision oncology', Frontiers in Immunology, 9, http://dx.doi.org/10.3389/fimmu.2018.02582
2018
Stirzaker C; Song JZ; Ng W; Du Q; Armstrong NJ; Locke WJ; Statham AL; French H; Pidsley R; Valdes-Mora F; Zotenko E; Clark SJ, 2017, 'Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer', Oncogene, 36, pp. 1328 - 1338, http://dx.doi.org/10.1038/onc.2016.297
2017
Valdés-Mora F; Gould CM; Colino-Sanguino Y; Qu W; Song JZ; Taylor KM; Buske FA; Statham AL; Nair SS; Armstrong NJ; Kench JG; Lee KML; Horvath LG; Qiu M; Ilinykh A; Yeo-Teh NS; Gallego-Ortega D; Stirzaker C; Clark SJ, 2017, 'Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer', Nature Communications, 8, http://dx.doi.org/10.1038/s41467-017-01393-8
2017
Valdés-Mora F; Locke WJ; Bandrés E; Gallego-Ortega D; Cejas P; García-Cabezas MA; Colino-Sanguino Y; Feliú J; del Pulgar TG; Lacal JC, 2017, 'Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer', Oncotarget, 8, pp. 26755 - 26770, http://dx.doi.org/10.18632/oncotarget.15815
2017
Colino-Sanguino Y; Clark SJ; Valdes-Mora F, 2016, 'H2A.Z acetylation and transcription: Ready, steady, go!', Epigenomics, 8, pp. 583 - 586, http://dx.doi.org/10.2217/epi-2016-0016
2016
Valdés-Mora F; Clark SJ, 2015, 'Prostate cancer epigenetic biomarkers: next-generation technologies', Oncogene, 34, pp. 1609 - 1618, http://dx.doi.org/10.1038/onc.2014.111
2015
Gallego-Ortega D; Ledger A; Roden DL; Law AMK; Magenau A; Kikhtyak Z; Cho C; Allerdice SL; Lee HJ; Valdes-Mora F; Herrmann D; Salomon R; Young AIJ; Lee BY; Sergio CM; Kaplan W; Piggin C; Conway JRW; Rabinovich B; Millar EKA; Oakes SR; Chtanova T; Swarbrick A; Naylor MJ; O’Toole S; Green AR; Timpson P; Gee JMW; Ellis IO; Clark SJ; Ormandy CJ, 2015, 'ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells', PLoS Biology, 13, http://dx.doi.org/10.1371/journal.pbio.1002330
2015
Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JMW; Nicholson RI; Print CG; Clark SJ; Musgrove EA, 2013, 'BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer', Molecular Cancer Therapeutics, 12, pp. 1874 - 1885, http://dx.doi.org/10.1158/1535-7163.MCT-13-0012
2013
Stone A; Valdes-Mora F; Clark SJ, 2013, 'Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer', Epigenomics, 5, pp. 595 - 598, http://dx.doi.org/10.2217/epi.13.70
2013
Kalyuga M; Gallego-Ortega D; Lee H; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Rosalind launchbury R; Statham A; Armstrong NJ; Alles MC; Adelaide young A; Egger A; Au W; Piggin CL; Evans C; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JMW; Robert i nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ, 2012, 'ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer', PLoS Biology, 10, pp. e1001461, http://dx.doi.org/10.1371/journal.pbio.1001461
2012
Stone A; Valdes-Mora F; Gee JM; Farrow L; Mcclelland RS; Fiegl H; Dutkowski C; McCloy RA; Sutherland RL; Musgrove EA; Robert i nicholson RI, 2012, 'Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer', PLoS One, 7, pp. e40466, http://dx.doi.org/10.1371/journal.pone.0040466
2012
Valdes-Mora F; Song JZ; Statham AL; Strbenac D; Robinson MD; Nair SS; Patterson K; Tremethick DJ; Stirzaker C; Clark SJ, 2012, 'Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer', Genome Research, 22, pp. 307 - 321, http://dx.doi.org/10.1101/gr.118919.110
2012
Valdés-Mora F; Gómez DPT; Lacal JC, 2011, 'TWIST1 (twist homolog 1 (Drosophila))', Atlas of Genetics and Cytogenetics in Oncology and Haematology, http://dx.doi.org/10.4267/2042/44846
2011
Valdés-Mora F; Gómez DPT; Lacal JC, 2011, 'CDC42 (cell division cycle 42 (GTP binding protein, 25kDa))', Atlas of Genetics and Cytogenetics in Oncology and Haematology, http://dx.doi.org/10.4267/2042/44606
2011
Gallego-Ortega D; Gómez del Pulgar T; Valdés-Mora F; Cebrián A; Lacal JC, 2011, 'Involvement of human choline kinase alpha and beta in carcinogenesis: A different role in lipid metabolism and biological functions', Advances in Enzyme Regulation, 51, pp. 183 - 194, http://dx.doi.org/10.1016/j.advenzreg.2010.09.010
2011
Lee HJ; Hinshelwood R; Bouras T; Gallego-Ortega D; Valdes-Mora F; Blazek K; Visvader JE; Clark SJ; Ormandy CJ, 2011, 'Lineage specific methylation of the Elf5 promoter in mammary epithelial cells', Stem Cells, 29, pp. 1611 - 1619, http://dx.doi.org/10.1002/stem.706
2011
Valdés-Mora F; Gómez Del Pulgar T; Bandrés E; Cejas P; Ramírez De Molina A; Pérez-Palacios R; Gallego-Ortega D; García-Cabezas MA; Casado E; Larrauri J; Nistal M; González-Barón M; García-Foncillas J; Lacal JC, 2009, 'TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer', Annals of Surgical Oncology, 16, pp. 78 - 87, http://dx.doi.org/10.1245/s10434-008-0166-x
2009
Gallego-Ortega D; de Molina AR; Ramos MA; Valdes-Mora F; Barderas MG; Sarmentero-Estrada J; Lacal JC, 2009, 'Differential role of human choline kinase α and β enzymes in lipid metabolism: Implications in cancer onset and treatment', PLoS ONE, 4, http://dx.doi.org/10.1371/journal.pone.0007819
2009
Gómez Del Pulgar T; Valdés-Mora F; Bandrés E; Pérez-Palacios R; Espina C; Cejas P; García-Cabezas MA; Nistal M; Casado E; González-Barón M; García-Foncillas J; Lacal JC, 2008, 'Cdc42 highly expressed in colorectal adecarcinoma and downregulates ID4 through an epigenetic mechanism', International Journal of Oncology, 33, pp. 185 - 193
2008
Gallego-Ortega D; de Molina AR; Ramos MA; Valdes-Mora F; Sarmentero-Estrada J; Lacal JC, 2008, 'Differential role of choline kinase alpha and beta isoforms in human carcinogenesis', European Journal of Cancer Supplements, 6, pp. 26 - 26, http://dx.doi.org/10.1016/s1359-6349(08)71275-8
2008
Gómez del Pulgar T; Bandrés E; Espina C; Valdés-Mora F; Pérez-Palacios R; García-Amigot F; García-Foncillas J; Lacal JC, 2007, 'Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer', International Journal of Biochemistry and Cell Biology, 39, pp. 2289 - 2302, http://dx.doi.org/10.1016/j.biocel.2007.06.014
2007
Conference Papers
add
Persson M; Jackson E; Duchatel R; Bramberger L; McEwen H; Kearney P; Findlay I; Douglas A; Kobbe B; Wagener R; Larsen M; Faridi P; Holst J; Mayall J; Gedye C; Hondermarck H; Horvat J; Nixon B; Cartaxo R; Koschmann C; Valdes-Mora F; Ortega DG; Nazarian J; Alonso MM; Hulleman E; Van der Lugt J; Vitanza N; Mueller S; Dun M, 2022, 'ANTAGONISM OF DRD2 USING ONC201 INCREASED EXPRESSION OF ANTIGEN PRESENTATION PATHWAY PROTEINS IN DIFFUSE MIDLINE GLIOMA, RECRUITING TUMOR INFILTRATING LYMPHOCYTES IN VIVO', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, FL, Tampa, pp. 272 - 272, presented at 27th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), FL, Tampa, 16 November 2022 - 20 November 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000888571001365&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Ortega DG; Ledger A; Roden D; Cho C; Allerdice S; Lee H; Valdes-Mora F; Salomon R; Oakes S; Ormandy C, 2014, 'THE ETS TRANSCRIPTION FACTOR ELF5 IS A KEY DETERMINANT OF THE LETHAL PHENOTYPE IN LUMINAL BREAST CANCER, DRIVING THE ACQUISITION OF ANTIESTROGEN RESISTANCE AND METASTATIC ACTIVITY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 16 - 17, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Valdes-Mora F; Gomez del Pulgar T; Bandres E; Cejas P; Ramirez de Molina A; Perez-Palacios R; Gallego-Ortega D; Angel Garcia-Cabezas M; Garcia-Foncillas J; Carlos Lacal J, 2008, 'TWIST1 overexpression is associated with nodal invasion and male gender in primary colorectal cancer', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, FRANCE, Lyon, pp. 154 - 154, presented at 20th Meeting of the European-Association-for-Cancer-Research, FRANCE, Lyon, 05 July 2008 - 08 July 2008, http://dx.doi.org/10.1016/S1359-6349(08)71767-1
2008
Working Papers
add
Vafaee F, 2021, Disentangling single-cell omics representation with a power spectral density-based feature extraction, http://dx.doi.org10.1101/2021.10.25.465657
2021
Book Chapters
add
Valdés-Mora F; Stirzaker C, 2018, 'Epigenetic Alterations in Primary Prostate Cancer', in Molecular Pathology Library, Springer International Publishing, pp. 193 - 211, http://dx.doi.org/10.1007/978-3-319-64096-9_13
2018
Valdes-Mora F; Lee HJ, 2016, 'Single-Cell Genomics and Epigenomics', in Tseng FG; Santra TS (ed.), Essentials of Single-Cell Analysis Concepts, Applications and Future Prospects, edn. Series in BioEngineering, SPRINGER-VERLAG BERLIN, pp. 257 - 301, http://dx.doi.org/10.1007/978-3-662-49118-8_10
2016
Conference Abstracts
add
Gallego-Ortega D; Ledger A; Roden D; Cho C; Allerdice SL; Lee HJ; Valdes-Mora F; Lee B; Kaplan W; Salomon R; Piggin C; Rabinovich B; Millar E; Chtanova T; Swarbrick A; Clark S; Ormandy C, 2015, 'The ETS transcription factor ELF5 drives metastasis via angiogenesis and recruitment of Gr-1+ CD11b+ myeloid derived suppressor cells in luminal breast cancer', in Clinical and Experimental Metastasis, Springer Verlag (Germany), Vol. 32, pp. 203 - 203, presented at MRS 15th International biennial congress of the metastasis research society, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000351601900067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2015

2021-2023. Co-Investigator 2. Investigator initiated Research Scheme. National Breast Cancer Foundation. (3 years, $393,078). Ranked Top 1 nationally.

2021-2022. CIA. The Cure Starts Now. (1 year, $150, 379)

2020-2021. Co-Investigator Seed Funding Award UNSW Cellular Genomics Futures Institute. (1 year, $100,000). CIA Dr Fatemeh Vafaee.

2020. Co-Investigator 3R project UNSW. (1 year, $65,000). CIA Dr David Gallego Ortega

2019-2021. Cancer Institute NSW Career Development Fellowship (CDF181218, 3 years $ 600,000). Sole CIA

2018-2020. Co-Investigator B in NHMRC project grant (APP1144574, 3 years $ 859,350). CIA Prof Susan Clark.

2014-2016. Co-Investigator B in NHMRC project grant (APP1063560, 3 years $591,599). CIA Prof Susan Clark.

2011-2013. Co-Investigator of Prostate Cancer Foundation of Australia Project Grant. (PG4310. 3 years, $ 375K). CIA Prof Susan Clark.

2013-2018. National Breast Cancer Foundation/ Cure Cancer Australia Foundation Postdoctoral Training Fellowship (PF-13-11. 4 years excluding career disruption, $400K). Sole CIA

Organisational units